CHGX Stock Overview
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ChitogenX Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.065 |
| 52 Week High | CA$0.17 |
| 52 Week Low | CA$0.03 |
| Beta | 0.49 |
| 1 Month Change | 0% |
| 3 Month Change | -31.58% |
| 1 Year Change | -61.76% |
| 3 Year Change | -84.52% |
| 5 Year Change | -82.89% |
| Change since IPO | -93.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHGX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 62.5% | -5.8% | -0.6% |
| 1Y | -61.8% | -37.3% | 3.9% |
Return vs Industry: CHGX underperformed the Canadian Biotechs industry which returned -37.3% over the past year.
Return vs Market: CHGX underperformed the Canadian Market which returned 3.9% over the past year.
Price Volatility
| CHGX volatility | |
|---|---|
| CHGX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 13.6% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: CHGX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CHGX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Pierre Laurin | www.chitogenx.com |
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022.
ChitogenX Inc. Fundamentals Summary
| CHGX fundamental statistics | |
|---|---|
| Market cap | CA$5.40m |
| Earnings (TTM) | -CA$3.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs CHGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHGX income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$3.26m |
| Earnings | -CA$3.26m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.039 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -58.3% |
How did CHGX perform over the long term?
See historical performance and comparison